Adana Pharma

Adana Pharmaceuticals was a clinical-stage biopharmaceutical company based in San Diego, California, that specialized in the development of innovative inhaled therapies for respiratory diseases. The company's primary focus was its lead candidate, ADNA-101, a bifunctional muscarinic antagonist-beta2 agonist (MABA) designed to provide potent bronchodilation in a single molecule for patients with COPD and asthma. By integrating two complementary mechanisms of action, Adana sought to improve patient adherence and clinical efficacy compared to existing combination therapies. The company was led by a management team with extensive experience in the respiratory space, including veterans from Pearl Therapeutics. Adana Pharmaceuticals was officially dissolved in late 2021.